Lindenmaier Laurence B, Philbrick Kenneth A, Branscum Adam J, Kalra Satya P, Turner Russell T, Iwaniec Urszula T
Skeletal Biology Laboratory, School of Biological and Population Health Sciences, Oregon State University , Corvallis, OR , USA.
Biostatistics Program, School of Biological and Population Health Sciences, Oregon State University , Corvallis, OR , USA.
Front Endocrinol (Lausanne). 2016 Aug 16;7:110. doi: 10.3389/fendo.2016.00110. eCollection 2016.
Low bone mass is often associated with elevated bone marrow adiposity. Since osteoblasts and adipocytes are derived from the same mesenchymal stem cell (MSC) progenitor, adipocyte formation may increase at the expense of osteoblast formation. Leptin is an adipocyte-derived hormone known to regulate energy and bone metabolism. Leptin deficiency and high-fat diet-induced obesity are associated with increased marrow adipose tissue (MAT) and reduced bone formation. Short-duration studies suggest that leptin treatment reduces MAT and increases bone formation in leptin-deficient ob/ob mice fed a regular diet. Here, we determined the long-duration impact of increased hypothalamic leptin on marrow adipocytes and osteoblasts in ob/ob mice following recombinant adeno-associated virus (rAAV) gene therapy. Eight- to 10-week-old male ob/ob mice were randomized into four groups: (1) untreated, (2) rAAV-Lep, (3) rAAV-green fluorescent protein (rAAV-GFP), or (4) pair-fed to rAAV-Lep. For vector administration, mice were injected intracerebroventricularly with either rAAV-leptin gene therapy (rAAV-Lep) or rAAV-GFP (9 × 10(7) particles) and maintained for 30 weeks. In a second study, the impact of increased hypothalamic leptin levels on MAT was determined in mice fed high-fat diets; ob/ob mice were randomized into two groups and treated with either rAAV-Lep or rAAV-GFP. At 7 weeks post-vector administration, half the mice in each group were switched to a high-fat diet for 8 weeks. Wild-type (WT) controls included age-matched mice fed regular or high-fat diet. High-fat diet resulted in a threefold increase in MAT in WT mice, whereas MAT was increased by leptin deficiency up to 50-fold. Hypothalamic leptin gene therapy increased osteoblast perimeter and osteoclast perimeter with minor change in cancellous bone architecture. The gene therapy decreased MAT levels in ob/ob mice fed regular or high-fat diet to values similar to WT mice fed regular diet. These findings suggest that leptin plays an important role in regulating the differentiation of MSCs to adipocytes and osteoblasts, a process that may be dysregulated by high-fat diet. However, the results also illustrate that reducing MAT by increasing leptin levels does not necessarily result in increased bone mass.
低骨量通常与骨髓脂肪增多有关。由于成骨细胞和脂肪细胞都来源于同一个间充质干细胞(MSC)祖细胞,脂肪细胞的形成可能会以成骨细胞的形成为代价而增加。瘦素是一种由脂肪细胞分泌的激素,已知其可调节能量和骨代谢。瘦素缺乏和高脂饮食诱导的肥胖与骨髓脂肪组织(MAT)增加和骨形成减少有关。短期研究表明,在喂食常规饮食的瘦素缺乏ob/ob小鼠中,瘦素治疗可减少MAT并增加骨形成。在此,我们确定了重组腺相关病毒(rAAV)基因治疗后,下丘脑瘦素增加对ob/ob小鼠骨髓脂肪细胞和成骨细胞的长期影响。将8至10周龄的雄性ob/ob小鼠随机分为四组:(1)未治疗组,(2)rAAV-Lep组,(3)rAAV-绿色荧光蛋白(rAAV-GFP)组,或(4)与rAAV-Lep组配对喂食组。为了进行载体给药,给小鼠脑室内注射rAAV-瘦素基因治疗(rAAV-Lep)或rAAV-GFP(9×10⁷个颗粒),并维持30周。在第二项研究中,在喂食高脂饮食的小鼠中确定下丘脑瘦素水平升高对MAT的影响;将ob/ob小鼠随机分为两组,分别用rAAV-Lep或rAAV-GFP治疗。在载体给药后7周,每组一半的小鼠改为喂食高脂饮食8周。野生型(WT)对照组包括喂食常规或高脂饮食的年龄匹配小鼠。高脂饮食导致WT小鼠的MAT增加了三倍,而瘦素缺乏使MAT增加了50倍。下丘脑瘦素基因治疗增加了成骨细胞周长和破骨细胞周长,松质骨结构变化较小。基因治疗使喂食常规或高脂饮食的ob/ob小鼠的MAT水平降低至与喂食常规饮食的WT小鼠相似的值。这些发现表明,瘦素在调节MSC向脂肪细胞和成骨细胞的分化中起重要作用,这一过程可能因高脂饮食而失调。然而,结果也表明,通过增加瘦素水平来减少MAT不一定会导致骨量增加。